ONCT Jul 2024 7.500 call
| Previous Close | 0.0000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 2.3000 |
| Strike | 7.50 |
| Expire Date | 2024-07-19 |
| Day's Range | N/A - N/A |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
GlobeNewswireOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fourth dosing cohort will receive ON
- GlobeNewswire
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer. Oncternal’s President and CEO, James Breitmeyer, M.D., Ph.D. will join Oppenheimer Senior Research Biotech Analyst, Hartaj Singh and a prostate cancer Key Opinion Leader on Tu
Simply Wall St.Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Oncternal Therapeutics ( NASDAQ:ONCT ) Full Year 2023 Results Key Financial Results Net loss: US$39.5m (loss narrowed...
